We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
-0.2%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$279M
AUM Growth
-$15.1M
Cap. Flow
+$9.47M
Cap. Flow %
3.39%
Top 10 Hldgs %
54.03%
Holding
87
New
14
Increased
26
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$4.5M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.48M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$3.39M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$2.97M
5
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$2.93M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$5.49M
2
CRIS icon
Curis
CRIS
+$3.95M
3
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$2.96M
4
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$2.54M
5
CLDX icon
Celldex Therapeutics
CLDX
+$2.2M

Sector Composition

Rank Sector Weight
1 Healthcare 66.89%
2 Miscellaneous 28.58%
3 Financials 3.72%
4 Industrials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CEREW
51
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$1.04M 0.37%
72,466
– –
ZYME icon
52
Zymeworks
ZYME
$2.09B
$1.04M 0.37%
30,000
-50,000
-63% -$1.59M
NSTG
53
DELISTED
NanoString Technologies, Inc.
NSTG
$972K 0.35%
+15,000
New +$952K
BLU
54
DELISTED
BELLUS Health Inc.
BLU
$933K 0.33%
300,000
– –
QSI icon
55
Quantum-Si Incorporated
QSI
$168M
$920K 0.33%
75,000
-75,000
-50% -$786K
CHAQ.U
56
DELISTED
Chardan Healthcare Acquisition 2 Corp. Units, each consisting of one share of Common Stock, and one
CHAQ.U
$819K 0.29%
75,000
– –
ACHL
57
DELISTED
Achilles Therapeutics
ACHL
$783K 0.28%
80,000
+55,000
+220% +$746K
GBT
58
DELISTED
Global Blood Therapeutics, Inc.
GBT
$700K 0.25%
20,000
– –
HARP
59
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$694K 0.25%
5,000
+3,000
+150% +$572K
IMTXW
60
DELISTED
Immatics N.V. Warrants
IMTXW
$654K 0.23%
190,000
-10,000
-5% -$33.2K
ITOS
61
DELISTED
iTeos Therapeutics
ITOS
$641K 0.23%
+25,000
New +$596K
APLS
62
DELISTED
Apellis Pharmaceuticals
APLS
$632K 0.23%
+10,000
New +$516K
CTMX icon
63
CytomX Therapeutics
CTMX
$808M
$475K 0.17%
75,000
+25,000
+50% +$195K
IMVT icon
64
CALL
Immunovant
IMVT
$8.11B
$317K 0.11%
30,000
-40,000
-57% -$559K
SKINW
65
DELISTED
The Beauty Health Company Warrant expiring 5/4/2026
SKINW
$288K 0.1%
45,000
– –
CVRX icon
66
CVRx
CVRX
$81.3M
$210K 0.08%
+7,500
New +$210K
MSACW
67
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$34K 0.01%
+33,333
New +$26.4K
ASND icon
68
PUT
Ascendis Pharma A/S
ASND
$17.7B
– –
-20,000
Closed -$2.58M
BLUE
69
CALL
DELISTED
bluebird bio
BLUE
– –
-3,860
Closed -$1.51M
BYSI icon
70
BeyondSpring
BYSI
$25.4M
– –
-50,000
Closed -$554K
CCCC icon
71
C4 Therapeutics
CCCC
$463M
– –
-20,000
Closed -$740K
CRIS icon
72
CALL
Curis
CRIS
$3.27M
– –
-625
Closed -$2.83M
SNDX icon
73
CALL
Syndax Pharmaceuticals
SNDX
$1.84B
– –
-190,500
Closed -$4.26M
SPY icon
74
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
– –
-110,000
Closed -$43.6M
STRO icon
75
Sutro Biopharma
STRO
$333M
– –
-8,000
Closed -$1.82M
1 2
3
4

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q2 2021 Portfolio in Review

As of Q2 2021, Affinity Asset Advisors held 87 positions worth $279M, down 5.1% from $294M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Affinity Asset Advisors deployed $9.47M of net new capital in Q2 2021, opening 14 new positions and adding to 26 existing holdings. Its largest new stake was Medicus Sciences Acquisition Corp. Class A Ordinary Share: 300,000 shares worth $2.9M.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 63% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Curis, an estimated $3.95M trimmed.

  • Affinity Asset Advisors's largest Q2 2021 buy was Medicus Sciences Acquisition Corp. Class A Ordinary Share: 300,000 shares worth $2.9M.
  • Affinity Asset Advisors added most to Vincerx Pharma, Inc. Common Stock in Q2 2021, an estimated $4.5M increase.
  • Affinity Asset Advisors's biggest Q2 2021 reduction was Curis, cutting an estimated $3.95M.
  • Affinity Asset Advisors fully exited Travere Therapeutics in Q2 2021, selling an estimated $5.49M.
  • Affinity Asset Advisors's ten largest holdings make up 54% of its $279M portfolio in Q2 2021.
  • Affinity Asset Advisors opened 14 new positions and closed 18 in Q2 2021.
  • Affinity Asset Advisors's portfolio value fell 5.1% quarter-over-quarter to $279M.

Based on Affinity Asset Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.